success for avastin in europe, page-9

great news, thanks for clarification there nuts

avastin only seems to be specific to those who are platinum-resistant (platinum being a main constituent of common chemo), so not marketed for all OC sufferers

the fact that it only showed a PFS of 3.3 months greater than SoC is encouraging, especially given the relative lack of side effects that Cvac has

we really need final phaseIIb data to come in, and be positive.

time to commercialisation might be a way off, but if the phaseIIb data suggests that phase III will be significant, then you should expect a positive re-rating of the stock. but that is IF it is positive.....